Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
- : A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
- : Resverlogix Announces Presentations at Leading Scientific Conferences
- : Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet